Teva Pharmaceutical Industries Limited · TASE:TEVA
Teva Pharmaceutical Industries — Investor Day (May 2023)
77 slides from Teva Pharmaceutical Industries's investor day presentation, May 18, 2023
Slide 1: Pivot to Growth
PIVOT TO GROWTH Stronger. Bolder. Simpler. May 18th, 2023
Slide 2: Cautionary note regarding forward-looking statements
Cautionary note regarding forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainti
Slide 3: Agenda
Agenda Strategic outlook Step up innovation Funding growth Q&A Teva Executive Richard Francis Eric Hughes, MD, PhD Eli Kalif Management President & EVP, Global R&D & EVP, Chief Executive Officer Chief Medical Officer Chief Financial Officer 2
Slide 4: Pivot to growth
Pivot to growth Richard Francis President & Chief Executive Officer 3
Slide 5: We heard your concerns
We heard your concerns Top/bottom-line growth doesn't seem feasible We remain on the sidelines pending better conviction on Teva’s path to top- and bottom-line growth Pivot to growth Growth challenges persist 4 Source: Select analyst quotes 2022 - 2023
Slide 6: Turning the page on past uncertainties
Turning the page on past uncertainties • Net debt reduced to $18.5B (4.25x EBITDA) in Q1 2023 Leverage • Refinanced maturities • Substantial progress toward U.S. nationwide opioid settlement Litigations agreement • Settlement reached with 49/50 states Lack of innovative • FDA approval of UZEDY™ on A
Slide 7: We have untapped potential to drive long-term growth
We have untapped potential to drive long-term growth Strong commercial portfolio Promising innovative pipeline AUSTEDO, AJOVY, UZEDY and Strong innovative pipeline with proven upcoming biosimilars targets / mechanisms of action Solid core businesses Strong historical capabilities Strong generation o
Slide 8: Our strategic roadmap to growth
Our strategic roadmap to growth 2028+ Sustain growth 2025-2027 • Innovative launches (anti-TL1A, anti-PD1-IL2, anti-IL15) Accelerate growth • Sustainable innovative pipeline 2023-2024 • Innovative launches • Focused business development (olanzapine LAI, ICS/SABA) Return to growth • Margin expansion
Slide 9: Pivot to Growth
Pivot to Growth Deliver on Step up Sustain generics Focus our growth engines innovation powerhouse business • AUSTEDO • Late-stage pipeline • Global commercial • Capital allocation maximization delivery footprint toward growth drivers • UZEDY launch • Early-stage pipeline • Focused portfolio & • Tev
Slide 10: Deliver on our growth engines
Deliver on our growth engines Our near-term growth engines Deliver on our growth engines Biosimilars Goal to achieve >$2.5B Differentiated profile for Partnered & in-house revenue across tardive schizophrenia patients in a products targeting >$40B dyskinesia & Huntington's growing $4B LAI market opp
Slide 11: AUSTEDO: Ambition to achieve >$2.5B revenue
AUSTEDO Ambition to achieve >$2.5B revenue in large untapped market Deliver on our growth engines Largely under-treated and -diagnosed TD market Number of U.S. tardive dyskinesia patients in thousands (2022) TD Prevalence 785 Diagnosed patients 120 Treated patients >$2.5B 50 AUSTEDO revenue Treated
Slide 12: AUSTEDO: Going all in to maximize brand value
AUSTEDO Going all in to maximize brand value Deliver on our growth engines Holistic set of levers to reach >$2.5B revenue Commercial excellence including increased field force resources Enhanced patient support to improve conversion & adherence Streamlined titration regimen and XR launch this week R
Slide 13: UZEDY: Differentiated profile for schizophrenia patients
UZEDY Differentiated profile for Schizophrenia patients Deliver on our growth engines Invega Sustenna® Molecule risperidone paliperidone Efficacy Efficacy profile consistent with risperidone Efficacy profile consistent with paliperidone 3M Invega Trinza® Safety and 6M Invega Safety profile consisten
Slide 14: UZEDY: $4B U.S. market size for LAIs
UZEDY $4B U.S. market size with clear opportunity for LAIs Deliver on our growth engines Large market for long-acting injectables Number of U.S. patients in thousands (2022) Schizophrenia prevalence 2,433 Diagnosed patients 2,311 ~$4B Treated patients 1,618 785 Treated with 2nd generation antipsycho
Slide 15: Biosimilars: Extensive pipeline to capitalize on market opportunity
Biosimilars Extensive pipeline to capitalize on market opportunity Deliver on our growth engines Late stage – by 2027 Early Stage – post 2027 5 products in late-stage pipeline Near-term EU expansion to broaden portfolio and presence bStelara under FDA review Large opportunity - $300-400B of drug bPr
Slide 16: Biosimilars: Strong late-stage pipeline
Biosimilars Strong late-stage pipeline Deliver on our growth engines Commercialization Biosimilar 2022 U.S. originator Reference product Geographic scope2 model development status brand net revenue Humira Partnered with AlvoTech Filed1 ~$19B Partnered with AlvoTech Filed ~$6B Partnered with AlvoTech
Slide 17: Biosimilars: Addressing the >$100B market opportunity
Biosimilars Addressing the >$100B market opportunity Deliver on our growth engines Global commercial footprint battle-tested with previous products Proven capabilities & Large-scale manufacturing dedicated capabilities approach Partnership model to optimize development costs & risks 16
Slide 18: Select assets within our promising innovative pipeline
Step up innovation Select assets within our promising innovative pipeline Step up innovation Preclinical Phase I Phase II Phase III (select assets) Anti-IL15 (53408) Anti-TL1A (48574) LAI olanzapine (44749) Celiac Disease IBD (UC/CD) Schizophrenia Anti-PAR2 (56192) ICS/SABA (56248) Neuroscience Asth
Slide 19: Promising late-stage assets poised to accelerate growth
Promising late-stage assets poised to accelerate growth Step up innovation Teva unique capabilities Olanzapine LAI Potential to be first long-acting olanzapine Product formulation ('749) with a favorable safety profile H1 2025 – Phase III results ICS/SABA De-risked1 ICS/SABA fixed-dose Complex devic
Slide 20: Olanzapine LAI ('749): Potential first LAI olanzapine
Olanzapine LAI ('749) Potential to be the first LAI olanzapine with right safety profile Step up innovation 1990's Today olanzapine ('749) Oral olanzapine Zyprexa Relprevv® (LAI) Target profile Efficacy Expect efficacy consistent with olanzapine Expected in line with oral olanzapine2 Well characteri
Slide 21: ICS/SABA ('248): Large commercial opportunity
ICS/SABA ('248) Large commercial opportunity for fixed dose ICS/SABA Step up innovation • 10M+ U.S. Asthma patients treated with SABA 1 Market set-up • Recent GINA guidelines recommending to replace SABA by ICS & SABA $2.5B Strong • Drug-device combination expertise 2 capabilities • Established resp
Slide 22: Anti-TL1A ('574): Potential best-in-class in IBD
Anti-TL1A ('574) Potential for best-in-class in inflammatory bowel disease Step up innovation Large underserved market Expected anti-TL1A competitive profile 1 Promising pre-clinical data Showcasing potential to be best-in-class ~$25B 2 Well characterized safety & ADA profile from outcomes of Asthma
Slide 23: Generics business positioned for success
Sustain generics powerhouse Generics business positioned for success Sustain generics powerhouse Generics - North America 38% • Leadership in high value new generics launches • Large volume of upcoming LOEs Generics – Europe & International Markets $8.1B • Growing and profitable 50% Revenues in 2022
Slide 24: Making our generics business a sustainable powerhouse
Sustain generics powerhouse Global commercial footprint with focused portfolio Concentrate on high value products and best-in-class service level Exiting lowest contribution products Making our generics Focused pipeline business a sustainable High-value segments, U.S. paragraph IV, EU first to marke
Slide 25: Focusing our business: Clear strategic role per business
Focusing our business Clear strategic role per business Focus our business Generics & Legacy specialty Innovative Biosimilars Teva API Distribution OTC & Other • Gx NA • COPAXONE® • AUSTEDO • ANDA • Gx EU & IM • Respiratory • AJOVY • MEDIS • OTC • Other • UZEDY2 $8.1B $2.3B $1.3B $0.5B $0.7B1 $2.0B
Slide 26: Teva API: Leading API business
Teva API Leading API business Focus our business Limited Teva Strong Leading API Extensive dependency financials player portfolio on Teva API ~$1B 2022 revenue, incl. #2 Global API player ~350 APIs in the ~10% of Teva's products $0.3B from internal #1 in small molecules portfolio, including mono-sou
Slide 27: Teva API: Creating a standalone unit
Teva API Creating a standalone unit and maximizing value for Teva Focus our business Dedicated platform and management team • Integrated R&D and manufacturing capabilities • Higher speed, flexibility and agility • Platform to accelerate growth Outperform Market access extension market • Increased ac
Slide 28: Sustainability is integral to our long-term growth
Sustainability is integral to our long-term growth Supporting the health Improving the lives of Always acting in the best of people by patients interest of patients protecting the health of our planet Climate Action & Access to Health Compliance and Ethics Resilience and Medicines Sustainable Pharma
Slide 29: Step up innovation
Step up innovation Eric Hughes, MD, PhD Executive Vice President, Global R&D & Chief Medical Officer 28
Slide 30: Strategy to step up innovation
Strategy to step up innovation 1 Focus on therapeutic areas: neuroscience, immunology and immuno-oncology Leverage demonstrated Teva strengths: antibody engineering, product 2 formulations and complex devices 3 Accelerate the development of key innovative drugs 4 Reallocate resources from generics t
Slide 31: Select assets within our promising innovative pipeline
Select assets within our promising innovative pipeline Preclinical Phase I Phase II Phase III (select assets) Anti-IL15 (53408) Anti-TL1A (48574) LAI olanzapine (44749) Celiac Disease IBD (UC/CD) Schizophrenia Anti-PAR2 (56192) ICS/SABA (56248) Neuroscience Asthma Anle138b1 (56286) MSA ATTENUKINETM
Slide 32: Olanzapine LAI ('749): Complementing our anti-psychotic portfolio
Olanzapine LAI ('749) – Neuroscience Complementing our anti-psychotic portfolio Large market mainly covered by 4 drugs Complementing our anti-psychotic portfolio Number of U.S. schizophrenia patients treated with atypical antipsychotics1 in thousands (2022) 284 Others (16%) Olanzapine LAI (‘749) to
Slide 33: Olanzapine LAI: Technology with proven safety profile
Olanzapine LAI ('749) – Neuroscience Technology with proven safety profile, battle-tested with UZEDY SteadyTeq® technology Subcutaneous – potentially less susceptible to major blood vessel damage1 Precipitated polymers regulating olanzapine API release rate Promising Phase I PK results Proof-of-conc
Slide 34: Olanzapine LAI: Phase III trial powered to confirm safety data
Olanzapine LAI ('749) – Neuroscience Phase III trial powered to confirm safety data Large sample size: 640 Acute treatment phase Long-term safety phase patients2, ~3,600 (8 weeks) (up to 48 weeks) injections Dose 1 TEV-44749 q1m Dose 1 TEV-44749 q1m Long-term efficacy and safety to be confirmed: Dos
Slide 35: Anti-TL1A ('574): Remaining large unmet need in IBD
Anti-TL1A ('574) - Immunology Remaining large unmet need for patients in IBD Addressing Crohn’s disease and ulcerative colitis Underserved market, limited drug options Number of U.S. / EU51 / Japan patients in thousands (2022) Diagnosed patients 2,289 1,777 4,066 Treated patients 1,144 1,529 2,673 T
Slide 36: TL1A targeting is a validated mechanism of action
Anti-TL1A ('574) - Immunology TL1A targeting is a validated mechanism of action TL1A key role in inflammatory cascade and fibrosis in the gut through its DR3 receptor TL1A targeting already demonstrated in in-human study with potential relevance in wide range of auto-immune indications 35 DR3: Recep
Slide 37: Antibody designed for selective binding
Anti-TL1A ('574) - Immunology Antibody designed for selective binding TL1A binding to two receptors '574 carefully designed to preferentially block DR3 and not DcR3 DR3 receptor DcR3 decoy receptor '574 TL1A Xray structure Desirable to block Desirable to retain • Human antibody with sub-nM '574 bind
Slide 38: High selectivity to DR3 and high potency confirmed in vitro
Anti-TL1A ('574) - Immunology High selectivity to DR3 and high potency confirmed in vitro '574 more selective than comparative reagent1, 2 '574 more potent than comparative reagent1, 6 TEV '574 DR3:DcR3 Anti-TL1A #11, 3 DR3:DcR3 TEV '574 vs. Anti-TL1A #21, 7 100 100 150 (TL1A-induced response) % com
Slide 39: Strong TL1A inhibition confirmed in animal model
Anti-TL1A ('574) - Immunology Strong TL1A inhibition confirmed in animal model Rapid and sustained clearance of free TL1A in non-human primate study 125 • Non-human primates received a single dose (n=4) 100 Free TL1A in serum (pg/mL) • TEV-48574 rapidly reduced free TL1A 75 50 • Prolonged reduction
Slide 40: Ambition to obtain best-in-class profile
Anti-TL1A ('574) - Immunology Ambition to obtain best-in-class profile • Greater potency vs. comparative reagents in in vitro assays1 Best-in-class preclinical profile • >100x selectivity for DR3 (vs. decoy) • Reduction of fibrosis in animal models2 • Comparable adverse events incidence vs. placebo
Slide 41: Phase II interim analysis expected H2 2024
Anti-TL1A ('574) - Immunology Phase II interim analysis expected H2 2024 Primary endpoints: Clinical remission (UC) & Endoscopic Dose-Range Finding induction1 Response (CD)3 (14 weeks) Dose 1 TEV-48574 + background therapy n=280 patients: 140 in UC & 140 Loading dose in CD2 Dose 2 TEV-48574 + backgr
Slide 42: Anti-IL15 ('408): Potential treatment for Celiac disease
Anti-IL15 (‘408) – Immunology Potential treatment for Celiac disease Celiac disease: IL15 over-expression driving Large burden of disease with no therapeutic option expansion of IELs and gut tissue damage Number of U.S. patients in thousands (2022) Celiac disease prevalence 2,006 Diagnosed patients
Slide 43: Anti-IL15: Phase I data showing potential best-in-class profile
Anti-IL15 (‘408) – Immunology Phase I data showing potential best-in-class profile Potential for differentiation Early evidence of IL15 blockade Phase I in healthy volunteers1 • Mean Free IL15 change from Baseline (%) High affinity for IL15 120 60 • Prolonged suppression of free IL15 0 • Potential f
Slide 44: ATTENUKINE: Proven technology for high efficacy, low toxicity
ATTENUKINE – Immuno-oncology Proven technology for high efficacy, low toxicity 1 Highly targeted Cytokine potency on target immune cells increased with targeting mAb 2 Reduced toxicity Cytokine potency on non-target cells reduced (100- 10,000x) via point mutations Potential application to a broad ar
Slide 45: ATTENUKINE (modakafusp alfa): Phase I/II results in Multiple Myeloma
ATTENUKINE (modakafusp alfa) – Immuno-oncology Phase I/II results in Multiple Myeloma provide proof of concept Targeting attenuated IFN-α directly to Ongoing Phase I/II for modakafusp alfa as a CD38+ immune Multiple Myeloma cells single agent (under development by Takeda)1 iinnovate-1 Phase I/II mod
Slide 46: ATTENUKINE ('278): Applying technology to solve IL2 paradigm
ATTENUKINE ('278) – Immuno-oncology Applying our ATTENUKINE tech to solve IL2 paradigm Attenukine Without Attenukine Free IL2 PD1 IL2 IL2 IL2 receptor receptor receptor receptor PD1+ CELL NON-TARGET CELL NON-TARGET CELL T-CELL STIMULATION NO STIMULATION BROAD T, NK CELL STIMULATION INCREASED IMMUNE
Slide 47: PD1-IL2 fusion for complete & lasting response in pre-clinical models
ATTENUKINE ('278) – Immuno-oncology PD1-IL2 fusion for complete & lasting response in pre-clinical models Linking PD1&IL2 for complete Lasting immune memory PD1 blockade not required for suppression of tumor growth1 without re-injection1 efficacy2 1,000 1,000 >1,500 Mean tumor volume (mm3) Mean tumo
Slide 48: Next milestones on our key pipeline assets
Next milestones on our key pipeline assets Olanzapine LAI Adult Phase III results H1 2025 TEV-44749 Anti-TL1A Phase II interim analysis H2 2024 TEV-48574 Anti-IL15 Phase I FIH SAD/MAD HV results H2 2024 TEV-53408 Anti-PD1-IL2 First patient enrolled in Phase I trial H1 2024 TEV-56278 ICS/SABA Phase I
Slide 49: Key takeaways – Step up innovation
Key takeaways – Step up innovation Exciting opportunities in late-stage pipeline (olanzapine LAI, ICS/SABA, anti-TL1A) Inflection point in early-stage pipeline (E.g., ATTENUKINE technology, anti-PD1-IL2 & anti-IL15) Pipeline to be enhanced by BD/in-licensing 48
Slide 50: Funding growth
Funding growth Eli Kalif Executive Vice President, Chief Financial Officer 49
Slide 51: We delivered on past commitments
We delivered on past commitments 2019 2022 Improved operating margin 24.5% +3.2pp 27.7% Significantly reduced net debt $24.9B -$6.5B $18.4B Brought down net debt/EBITDA ratio x5.3 -1.3 x4.0 50
Slide 52: Financial principles to achieve our growth strategy
Financial principles to achieve our growth strategy Support growth and cover our commitments Optimization of FCF Solid liquidity - $2.4B Portfolio optimization to repay debt and of maturities re- to invest in growth and invest in growth indexed on FCF business development Efficient generics Refinanc
Slide 53: We will optimize further our generics powerhouse
We will optimize further our generics powerhouse Simplification and focus of our portfolio • Reducing the number of product families covered • Adjusting our presence in geographic markets Improved FCF and cost base Adaptation of our manufacturing footprint • Closing of selected sites to reach 40-44
Slide 54: Generics manufacturing footprint optimization
Generics manufacturing footprint optimization Number of Teva manufacturing sites by year 80 19 52 40-44 16 61 36 2018 May 2023 New planned end-state Final dosage sites API & Bio sites 53
Slide 55: R&D spend and Innovative share to increase to support our growth
R&D spend and Innovative share to increase to support our growth 2022 2027 Current R&D allocation Expected R&D allocation Sources of Innovative ~10-20% R&D spend evolution ~20% Gx R&D reallocation ~40% ~10-20% Revenues base increase ~60-80% Margin expansion / ~40% mix evolution Biosimilars Innovativ
Slide 56: Solid liquidity position to support growth while meeting commitments
Solid liquidity position to support growth while meeting commitments Liquidity position as of 31st of March 23 – all values in $B Liquidity Gross debt – $20.7B 3.4 2.9 2.5 Average FCF1 2.1 ~$2.1B 2.1 2.0 1.8 1.8 1.6 1.6 1.0 1.0 0.8 Cash & RCF 23 24 25 26 27 28 29 30 31 36 46 equivalents 2022 Liquidi
Slide 57: Capital allocation: Meeting our commitments while funding growth
Capital allocation Meeting our commitments while funding growth Debt repayment and 1 net working capital enhancement Cash flow from operations Investment in our growth engines 2 (AUSTEDO, AJOVY, UZEDY, etc.) Portfolio optimization Investment in R&D and 3 business development 56
Slide 58: Our financial targets for 2027
Our financial targets for 2027 Net debt/ Operating adjusted Cash-to- Revenue growth income margin1, 2 EBITDA2 earnings2, 3, 4 Mid-single digit 30% 2.0x 80% 1. Operating income margin = Non-GAAP operating income divided by net revenues; excluding potential impact of BD depending on timing 2. All meas
Slide 59: Key takeaways – Funding Growth
Key takeaways – Funding Growth Building room to maneuver to reinvest in growth, while meeting commitments Clear capital allocation Financial commitments for 2027 58
Slide 60: Conclusion
Conclusion Richard Francis President & Chief Executive Officer 59
Slide 61: We are making clear choices
We are making clear choices Synergetic Growth enablers Growth drivers Standalone businesses Generics & Legacy specialty Innovative Biosimilars Teva API Distribution OTC & Other Re-allocation of cash and capital toward growth drivers Note: Innovative includes AUSTEDO, AJOVY, and innovative pipeline a
Slide 62: Pivot to growth
Pivot to growth Risk-adjusted topline impact - Illustrative $14.9B Mid- single digit growth Teva 2022 Legacy Generics Biosimilars Innovative Potential Teva 2027 BD deals 61 Note: Disclaimer - for illustrative purpose only - not intended to be at scale and subject to change and business constraints.
Slide 63: Teva tomorrow: stronger, bolder, simpler
Teva tomorrow: stronger, bolder, simpler Stronger Bolder Simpler Sustainable Gx Doubling our Innovative Focused resource Powerhouse business allocation • Stabilized revenue, • Bolstered growth • Teva API standalone steady cash flow • Sustainable pipeline • Resources allocated • Optimized margins tow
Slide 64: Questions & answers
Questions & answers Teva executive management
Slide 65: teva
teva
Slide 66: Appendix: Epidemiology Pack
APPENDIX Epidemiology Pack teva
Slide 67: AUSTEDO – Tardive Dyskinesia
AUSTEDO® – Tardive Dyskinesia 2022 number of U.S. & EU patients (thousands) TD prevalence 785 709 1,494 Diagnosed patients 120 80 200 Treated patients 50 63 113 Treated with VMAT2 41 11 52 inhibitor 0 500 1,000 1,500 U.S. EU VMAT2: Vesicular monoamine transporter 2 66 Source: Cerner Enviza TD and HD
Slide 68: AUSTEDO – Huntington's disease with chorea
AUSTEDO® – Huntington's disease with chorea 2022 number of U.S. patients (thousands) HD prevalence 72 Diagnosed patients 44 HD with chorea 30 Treated patients 15 Treated with VMAT2 5 inhibitor 0 20 40 60 80 67 VMAT2: Vesicular monoamine transporter 2 Source: Cerner Enviza TD and HD chorea Patient An
Slide 69: UZEDY – Schizophrenia LAIs
UZEDY® – Schizophrenia LAIs 2022 number of U.S. patients (thousands) Schizophrenia prevalence 2,433 Diagnosed patients 2,311 Treated patients 1,618 Treated with 2nd generation 214 antipsychotics LAIs 0 500 1,000 1,500 2,000 2,500 LAI: Long-Acting Injectable 68 Source: DRG Clarivate (2022)
Slide 70: Olanzapine ('749) – Schizophrenia treated with olanzapine
Olanzapine ('749) – Schizophrenia treated with olanzapine 2022 number of U.S. patients (thousands) Schizophrenia prevalence 2,433 Diagnosed patients 2,311 Treated patients 1,618 Treated with 321 Olanzapine 0 500 1,000 1,500 2,000 2,500 Note: Patients on olanzapine include patients on oral, LAI and o
Slide 71: Anti-TL1A ('574) – Ulcerative colitis (IBD)
Anti-TL1A ('574) – Ulcerative colitis (IBD) 2022 number of U.S. / EU51 / Japan patients (thousands) Diagnosed patients 2,289 Treated patients 1,144 Treated with 245 targeted therapy 0 500 1,000 1,500 2,000 2,500 IBD: Inflammatory Bowel Disease 70 1. France, Germany, Italy, Spain & United Kingdom Sou
Slide 72: Anti-TL1A ('574) – Crohn's disease (IBD)
Anti-TL1A ('574) – Crohn's disease (IBD) 2022 number of U.S. / EU51 / Japan patients (thousands) Diagnosed patients 1,777 Treated patients 1,529 Treated with 530 targeted therapy 0 500 1,000 1,500 2,000 IBD: Inflammatory Bowel Disease 71 1. France, Germany, Italy, Spain & United Kingdom Source: DRG
Slide 73: Anti-IL15 ('408) – Celiac Disease
Anti-IL15 ('408) – Celiac Disease 2022 number of U.S. patients (thousands) Coeliac Disease 2,006 prevalence Diagnosed patients 456 0 500 1,000 1,500 2,000 2,500 72 Source: DRG Clarivate (2022)
Slide 74: ICS/SABA ('248) – Asthma
ICS/SABA ('248) – Asthma 2022 number of U.S. patients (thousands) Diagnosed 15,218 asthma patients Treated patients 12,557 Treated with SABA 10,422 0 5,000 10,000 15,000 20,000 73 Source: DRG Clarivate (2022)
Slide 75: Appendix: Complete Innovative & Biosimilar pipeline
APPENDIX Complete Innovative & Biosimilar pipeline
Slide 76: Teva complete Innovative Medicine Pipeline
Teva complete Innovative Medicine Pipeline By development stage – as of May 1, 2023 Under Regulatory Preclinical Phase 1 Phase 2 Phase 3 Pre-Submission Review TEV-56278 TEV-53408 Anti-TL1-A Olanzapine LAI Digihaler® Digihaler® Oncology Gastrointestinal (TEV-48574) Schizophrenia (beclomethasone (bude
Slide 77: Teva Biosimilar Franchise
Teva Biosimilar Franchise By development stage – as of May 1, 2023 Under Regulatory Commercial Biosimilar Preclinical Phase 1 Phase 3 Under Regulatory Pre-Submission Preclinical Phase 3 Review Products1, 2 Review TEV-56285 Biosimilar to Prolia® Biosimilar to & Xgeva ® Humira® TEV-54142 (denosumab) (
Teva Pharmaceutical Industries — Investor Day (May 2023) on 6ix